325 related articles for article (PubMed ID: 19380403)
21. Breast cancer therapy: the role of PET-CT in decision making.
Pons F; Duch J; Fuster D
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):210-23. PubMed ID: 19293769
[TBL] [Abstract][Full Text] [Related]
22. Time-to-time correlation of high-risk atherosclerotic lesions identified with [(18)F]-FDG-PET/CT.
Wassélius J; Larsson S; Jacobsson H
Ann Nucl Med; 2009 Jan; 23(1):59-64. PubMed ID: 19205839
[TBL] [Abstract][Full Text] [Related]
23. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
24. A Potential Role for F-18 FDG PET/CT in Evaluation and Management of Fibrosing Mediastinitis.
Takalkar AM; Bruno GL; Makanjoula AJ; El-Haddad G; Lilien DL; Payne DK
Clin Nucl Med; 2007 Sep; 32(9):703-6. PubMed ID: 17710023
[TBL] [Abstract][Full Text] [Related]
25. Physiologic thymic uptake of 18F-FDG in children and young adults: a PET/CT evaluation of incidence, patterns, and relationship to treatment.
Jerushalmi J; Frenkel A; Bar-Shalom R; Khoury J; Israel O
J Nucl Med; 2009 Jun; 50(6):849-53. PubMed ID: 19443604
[TBL] [Abstract][Full Text] [Related]
26. Splenic infarction mimicking a necrotizing metastasis of malignant melanoma on F-18 FDG PET/CT.
Ahmadzadehfar H; Brockmann H; Schmiedel A; Biersack HJ; Ezziddin S
Clin Nucl Med; 2008 Aug; 33(8):571-2. PubMed ID: 18645383
[No Abstract] [Full Text] [Related]
27. Single 20-second acquisition of deep-inspiration breath-hold PET/CT: clinical feasibility for lung cancer.
Torizuka T; Tanizaki Y; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Ouchi Y
J Nucl Med; 2009 Oct; 50(10):1579-84. PubMed ID: 19759111
[TBL] [Abstract][Full Text] [Related]
28. Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas: changing the paradigms of treatments?
Coleman M; Kostakoglu L
Cancer; 2006 Oct; 107(7):1425-8. PubMed ID: 16933331
[TBL] [Abstract][Full Text] [Related]
29. PET and PET/CT studies of tumor tissue oxygenation.
Krause BJ; Beck R; Souvatzoglou M; Piert M
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):28-43. PubMed ID: 16557202
[TBL] [Abstract][Full Text] [Related]
30. Response to therapy in breast cancer.
Avril N; Sassen S; Roylance R
J Nucl Med; 2009 May; 50 Suppl 1():55S-63S. PubMed ID: 19380410
[TBL] [Abstract][Full Text] [Related]
31. Giant cell arteritis on 18F-FDG PET/CT.
Heston TF; Szabo Z
Clin Physiol Funct Imaging; 2009 Sep; 29(5):382-4. PubMed ID: 19522856
[TBL] [Abstract][Full Text] [Related]
32. Imaging in multiple myeloma.
Delorme S; Baur-Melnyk A
Eur J Radiol; 2009 Jun; 70(3):401-8. PubMed ID: 19272726
[TBL] [Abstract][Full Text] [Related]
33. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG
J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035
[TBL] [Abstract][Full Text] [Related]
34. F-18 FDG PET/CT findings in a patient with bilateral orbital and gastric mucosa-associated lymphoid tissue lymphomas.
Suga K; Yasuhiko K; Hiyama A; Takeda K; Matsunaga N
Clin Nucl Med; 2009 Sep; 34(9):589-93. PubMed ID: 19692819
[TBL] [Abstract][Full Text] [Related]
35. FDG-PET and PET/CT in the clinical management of gastrointestinal stromal tumor.
Basu S; Mohandas KM; Peshwe H; Asopa R; Vyawahare M
Nucl Med Commun; 2008 Dec; 29(12):1026-39. PubMed ID: 18987522
[TBL] [Abstract][Full Text] [Related]
36. The evolving role of PET-CT in the management of esophageal cancer.
Chuang HH; Macapinlac HA
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):201-9. PubMed ID: 19293768
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography/computed tomography: the current technology and applications.
Mittra E; Quon A
Radiol Clin North Am; 2009 Jan; 47(1):147-60. PubMed ID: 19195540
[TBL] [Abstract][Full Text] [Related]
38. Impact of fluorodeoxyglucose PET on the management of esophageal cancer.
Salavati A; Basu S; Heidari P; Alavi A
Nucl Med Commun; 2009 Feb; 30(2):95-116. PubMed ID: 19194210
[TBL] [Abstract][Full Text] [Related]
39. Comparison of 18F-FDG positron emission tomography and computed tomography in patients with colorectal carcinoma and lymphoma: our initial clinical experience.
Coha B; Radmilović K; Gardasanić J; Daković M; Stefanić M; Latić A; Mitrecić D
Acta Clin Croat; 2009 Mar; 48(1):35-9. PubMed ID: 19623870
[TBL] [Abstract][Full Text] [Related]
40. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.
Karam M; Ata A; Irish K; Feustel PJ; Mottaghy FM; Stroobants SG; Verhoef GE; Chundru S; Douglas-Nikitin V; Oliver Wong CY; Brepoels LM
Nucl Med Commun; 2009 Oct; 30(10):770-8. PubMed ID: 19657307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
